Abstract:In the last few decades, the pathogenesis of inflammatory bowel disease (IBD) in genetically predisposed subjects susceptible to specific environmental factors has been attributed to disturbance of both the immune and non-immune system and/or to the imbalanced interactions with microbes. However, increasing evidences support the idea that defects in pro-resolving pathways might strongly contribute to IBD onset. The resolution of inflammation is now recognized as a dynamic event coordinated by specialized pro-resolving lipid mediators (LMs), which dampen inflammation-sustaining events, such as angiogenesis, release of pro-inflammatory cytokines, clearance of apoptotic cells, and microorganisms. Among these pro-resolving molecules, those derived from essential polyunsaturated fatty acids (PUFAs) have been shown to induce favorable effects on a plethora of human inflammatory disorders, including IBD. Here, we offer a summary of mechanisms involving both cellular and molecular components of the immune response and underlying the anti-inflammatory and pro-resolving properties of PUFAs and their derivatives in the gut, focusing on both ω-3 and ω-6 LMs. These fatty acids may influence IBD progression by: reducing neutrophil transmigration across the intestinal vasculature and the epithelium, preventing the release of pro-inflammatory cytokines and the up-regulation of adhesion molecules, and finally by promoting the production of other pro-resolving molecules. We also discuss the numerous attempts in using pro-resolving PUFAs to ameliorate intestinal inflammation, both in patients with IBD and mouse models. Although their effects in reducing inflammation is incontestable, results from previous works describing the effects of PUFA administration to prevent or treat IBD are controversial. Therefore, more efforts are needed not only to identify and explain the physiological functions of PUFAs in the gut, but also to unveil novel biosynthetic pathways of these pro-resolving LMs that may be dysregulated in these gut-related disorders. We suppose that either PUFAs or new medications specifically promoting resolution-regulating mediators and pathways will be much better tolerated by patients with IBD, with the advantage of avoiding immune suppression.

Resolvins and protectins: natural pharmacophores for resolution biology

Resolvins: Anti-Inflammatory and Proresolving Mediators Derived from Omega-3 Polyunsaturated Fatty Acids

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Pro-resolving lipid mediators are leads for resolution physiology

Resolvins and protectins in the termination program of acute inflammation

Specialized pro-resolving mediator network: an update on production and actions

Resolvin E1 and protectin D1 activate inflammation-resolution programmes

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Specialized pro-resolving mediators - Key players in resolution

[Mechanism of Resolvins in Reducing the Inflammation Reaction in Inflammatory Diseases].

Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Proresolving Lipid Mediators in the Respiratory System

Old and new generation lipid mediators in acute inflammation and resolution